Clinical Trial for Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis and Active Psoriatic Arthritis.

Who may participate

Each clinical study has its own guidelines for who may participate, called eligibility criteria. These factors can include your age, sex, overall health, type and stage of disease, and personal treatment history. However, only the research study staff can determine if you qualify to enroll in the study.

Condition

Active Moderate to Severe Rheumatoid Arthritis, Active Ankylosing Spondylitis, Active Psoriatic Arthritis

Sex

Male or Female

Age

18+ years

Healthy participants

Eligibility criteria

Inclusion criteria

Patients must meet all of the following inclusion criteria to be eligible for inclusion in the study:

Xeljanz® XR is administered according to indications on the approved labeling
- Treatment of moderate to severe active RA in adult patients (18 years of age or older) who have had an inadequate response or are intolerant to methotrexate
- In combination with methotrexate, treatment of active psoriatic arthritis (PsA) in adult patients (18 years of age or older) who have had an inadequate response or who have been intolerant to a prior DMARD therapy.
- Treatment of active ankylosing spondylitis (AS) in adult patients (18 years of age or older) who have responded inadequately to conventional therapy
- In the following patients, Xeljanz® XR should be used only for patients who have had an inadequate response or are intolerant to the existing treatment.

A. Patients aged 65 or older B. Cardiovascular high-risk patients C. Patients at risk for malignancy

Patients who have previously been given Xeljanz 5mg, who have changed Xeljanz® XR, are also eligible for registration in the study
Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study

Exclusion criteria

Patients meeting any of the following criteria will not be included in the study:

Patients with a history of hypersensitivity to any ingredients of this product.
Patients with serious infection (sepsis, etc.) or active infection including localized infection.
Patients with active tuberculosis.
Patients with severe hepatic function disorder.
Patients with an absolute neutrophil count (ANC) <1,000 cells/mm3. \*
Patients with a lymphocyte count <500 cells/mm3. \*
Patients with a hemoglobin level <9 g/dL. \*
Pregnant or possibly pregnant women. \* Do not initiate Xeljanz XR in the following cases: ANC; absolute neutrophil count <1,000 cells/mm3 ALC; absolute lymphocyte count <500 cells/mm3 Hemoglobin<9 g/dL

Study overview

Xeljanz XR extended-release tablets 11 mg (Tofacitinib citrate) is a drug subject to the risk management plan in accordance with Article 4-1-11 of the "Regulation on Safety of Medicinal Products, etc." in Korea. As part of additional pharmacovigilance activity, this Post-marketing Surveillance (PMS) was planned to evaluate safety and effectiveness of Xeljanz XR under routine clinical practice. At least 200 patients with Rheumatoid Arthritis, Psoriatic Arthritis, or Ankylosing Spondylitis who were treated with Xeljanz XR will be enrolled about four years.

View locations for this study

Find the closest location, your results will be shown below

Find the closest location

Miles

0500

Nearest Locations found

1 site found

Pfizer

Seoul, South Korea

Recruiting

Site Info

Recruitment Status
Site details
Get direction
Study Contact
Clinical Trials ID

Recruitment Status
Site details
Study Contact
Clinical Trials ID

Join PfizerConnect

Korean Post-marketing Surveillance for Xeljanz XR

Who may participate

Eligibility criteria

Study overview

View locations for this study

Nearest Locations found

Join PfizerConnect

Korean Post-marketing Surveillance for Xeljanz XR

Who may participate

Eligibility criteria

Study overview

View locations for this study

Nearest Locations found

Are you a Healthcare Professional?